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Background: The treatment of hypertensive spontaneous intracranial hemorrhage (ICH) is still controversial. The
purpose of the present study was to investigate whether minimally invasive puncture and drainage (MIPD) could
improve patient outcome compared with decompressive craniectomy (DC).
Methods: Consecutive patients with ICH (≧30 mL in basal ganglia within 24 hours of ictus) were non-randomly
assigned to receive MIPD (group A) or DC (group B) hematoma evacuation. The primary outcome was death at
30 days after onset. Functional independence was assessed at 1 year using the Glasgow Outcome Scale.
Results: A total of 198 patients met the per protocol analysis (84 in group A and 114 in group B). The initial Glasgow
Coma Scale (GCS) score was 8.1 ± 3.4 and the National Institutes of Health Stroke Scale (NIHSS) score was 20.8 ± 5.3.
The mean hematoma volume (HV) was 56.7 ± 23.0 mL, and there was extended intraventricular hemorrhage (IVH) in
134 patients. There were no significant intergroup differences in the above baseline data, except group A had a higher
mean age than that of group B (59.4 ± 14.5 vs. 55.3 ± 11.1 years, P = 0.025).
The cumulative mortalities at 30 days and 1 year were 32.3% and 43.4%, respectively, and there were no significant
differences between groups A and B. However, the mortality for patients ≦60 years, NIHSS < 15 or HV≦60 mL was
significantly lower in group A than that in group B (all P < 0.05). The cumulative functional independence at 1 year
was 26.8%, and the difference between group A (33/84, 39.3%) and group B (20/114, 17.5%) was significant (P = 0.001).
Multivariate logistic regression analysis showed that a favorable outcome after 1 year was associated with the
difference in therapies, age, GCS, HV, IVH and pulmonary infection (all P <0.05).
Conclusions: For patients with hypertensive spontaneous ICH (HV≧30 mL in basal ganglia), MIPD may be a more
effective treatment than DC, as assessed by a higher rate of functional independence at 1 year after onset as well as
reduced mortality in patients ≦60 years of age, NIHSS < 15 or HV≦60 mL.
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Hypertensive intracranial hemorrhage (ICH) in the area of
the basal ganglia accounts for 50-70% of all spontaneous
ICH, and mortality at 30 days after onset is 33.3% to 50.6%,
[1,2] while 41% of survivors has some degree of disability
[3]. Hemostasis and clot removal achieved pathophysio-
logic benefits, including the prevention of hemorrhagic
expansion, reduction of intracranial pressure and clot mass
effect [4]. However, the optimal treatment choice for ICH,
medical or surgical, continues to be controversial.
The largest prospective randomized study, the STICH
trial [5], with 1033 patients from 107 centers over an
8-year period, indicated that surgical evacuation did
not appear to be helpful in treating supratentorial ICH.
The STICH II trial [6] was recently completed using
including 601 conscious patients with superficial lobar
intracerebral hemorrhages (10–100 mL) and without
intraventricular hemorrhage, who received either early
surgery or conservative treatment in a ratio of 1:1. This
trial showed no significant outcome differences at 6
moths between the two groups.
Surgical hematoma evacuation failed to demonstrate a
benefit to survival or morbidity, which may be attribut-
able to some additional damage incurred to uninjured
brain overlying the hematoma caused by the surgical
approach. To minimize this risk, minimally invasive
surgical strategies have been used.
A randomized controlled study by Miller et al. [7]
investigated 10 patients with ICH who received endo-
scopic aspiration or a conservative treatment and found
lower 6 month mortality in the endoscopic group than the
medical group. However, the efficacy in this very small
trial was limited to superficial lobe hematomas. Nishihara
et al. [8] found that endoscopic evacuation provided
better neurological outcomes than CT-guided stereotactic
hematoma removal. However, among their 27 cases in the
endoscopic group, more than 50% of the 15 patients with
a good outcome had a small subcortical or cerebellar
hemorrhage. The general outcomes of endoscopic and con-
servative treatments for basal ganglia hemorrhages have
been shown to have no significant difference between them
[9]. Thus, there is insufficient evidence to confirm that
these treatments can improve functional outcomes of ICH.
The optimal approach to remove a hematoma resulting
from ICH would be a rapid, simple method that combines
a high success rate with low risk and minimal cost. One
technique that may have such characteristics is minimally
invasive puncture and drainage (MIPD). MIPD is widely
used in China; however, few studies have compared the
efficacy of MIPD and DC for patients with hemorrhages
of 30 mL or more in the basal ganglia. The present study
was designed to investigate whether MIPD could improve
outcomes in these patients compared with the traditional
decompressive craniectomy (DC).Methods
Inclusion criteria
Patients were eligible for the study if they had a hyper-
tensive spontaneous ICH in the basal ganglia with a
hematoma volume (HV) ≧30 mL, the hematoma evacu-
ation could start within 24 hours of ictus (if the onset was
unobserved, it was considered to be at the last time the
patient was definitely normal), and the informed consent
for the operation could be obtained from patient’s relative
or guardian.
Exclusion criteria
Patients with ICH located in the cerebral lobes, infraten-
torial or subarachnoid areas of the brain; ICH caused by
trauma, aneurysms, arteriovenous malformation; ICH
secondary to an ischemic infarction or coagulopathy; or
patients with previous neurological defects or without
definite hypertension were excluded.
Patients
Consecutive patients with hypertensive spontaneous ICH
were non-randomly admitted to General Hospital of
the Beijing Military Region and Xianghe Hospital from
February 2009 to February 2012. The study was approved
by the Ethics Committee of General Hospital of Beijing
Military Region.
Grouping
Patients who presented to the General Hospital of the
Beijing Military Region were non-randomly admitted by
an emergency neurologist to the neurology department
to receive MIPD (group A) or to the neurosurgery depart-
ment to undergo DC (group B) hematoma evacuation.
Patients presented to the Xianghe hospital were admitted
to its neurology department to receive MIPD. The final
assignment of the group for each patient was determined
by the patient’s relative, who was presented with the risks
and benefits of each ICH treatment from the neurologist:
DC (general anesthesia, craniectomy, thorough hematoma
evacuation under direct vision), MIPD (local anesthesia,
minimal invasion, non direct vision, continuous drainage)
or conservative medical treatment. All MIPD procedures
in both hospitals were performed by the first author.
Baseline index definition and classification
Hypertension was judged to be present if the patient ful-
filled one of the following criteria: (1) treatment with anti-
hypertensive drugs, previously or currently; (2) repeated
measurements of systolic blood pressure >160 mmHg
or diastolic blood pressure >95 mmHg after admission.
Diabetes mellitus (DM) was assessed if the patient had
a history of DM or was taking anti-DM medications.
The scores from the Glasgow Coma Scale (GCS) were
classified into 3 categories: mild (15–13), moderate (12–7)
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Health Stroke Scale (NIHSS) were similarly classified: mild
(<15), moderate (15–20) and severe (>20).
ICH was diagnosed using a CT scan, with the hematoma
located in the basal ganglia (internal and/or external
capsule, caudate nucleus, thalamus, putamen, or more
than one of the above structures). HV was calculated from
the CT using the formula ABC/2, [10] where “A” and “B”
represent the length and width diameters, respectively, of
the largest hemorrhage slice, and “C” is the slice thickness,
in centimeters. We classified HV into 2 categories: ≦60 mL
and >60 mL. The degree of an extended intraventricular
hemorrhage (IVH) was classified into 4 categories, using
the methods described by Graeb [11]: 0, 1–4, 5–8 and
9–12 (from none to severe).
Time from onset to operation and complications,
including rebleed (RB), renal failure (RF), pulmonary




All patients received basal medical management, including
treatments for the control of cerebral edema, blood pres-
sure and glycemia; gastric cytoprotection; nutritional sup-
port; and the prevention of complications.
DC
Patients in group B received DC. After approximately
10*10 cm2 temporoparietal craniectomy, the dura was
opened in a cruciate manner; the hematoma was removed
microscopically with a suction device through the mid-
dle temporal gyrus. Active bleeding was controlled withFigure 1 Brain CT scan slice with the maximum hematoma area abov
shown. A: brain CT. Extension lines from the center (C) of the hematoma v
puncture (P) point are represented by CF and CP, respectively. Here, CF is p
is the puncture point. Puncture depth is the distance between C and P. B: a d
from F to P is equal to the CF line and parallel to the OML. The vertical length
from the OML to the maximum hematoma slice on the CT film.standard neurosurgical techniques. An external ventricular
drain tube was set into the lateral ventricle for drainage, if
IVH was present. The scalp was then closed.MIPD
Patients in group A underwent MIPD as follows: 1) The
body surface puncture site of the hematoma was deter-
mined based on the maximum hematoma slice on the
CT film (Figure 1), avoiding major vessels and import-
ant functional areas. 2) A YL-I puncture needle (Beijing
WanTeFu Medical Apparatus Co., Ltd. http://www.bjwtf.
com/en) was used; the length (mm) of the selected needle
matched with the depth from the temporal scalp to the
hematoma center. 3) After local anesthesia, the needle was
drilled into the center of the hematoma via the surface
localization puncture point, perpendicularly to the sagittal
plane. 4) The drill bit of the needle was removed and a
drainage tube was connected to the side hole of the
needle. A 5-mL syringe was connected to the other end of
the tube, and uncoagulated blood was gently aspirated. 5)
The hematoma cavity was rinsed with saline through an
ancillary washing needle. 6) Urokinase (10000 U)/saline
(3 mL) was infused into the clot, which was bathed for
1 hour and then drained into a closed collection bag. 7) A
follow-up CT scan was obtained 12–24 hours after MIPD.
Step 6 was repeated if residual blood remained, until
the hemorrhage was completely removed or until the
remaining HV was less than 10 mL (2–7 days were
generally required). Subsequently, the puncture needle
was removed and the puncture site was bandaged for
5–7 days. If severe IVH was present, lateral ventricular
external drainage was performed just after step 6.e the outer canthus-meatus line (OML) with the puncture point
ertically and horizontally outward to the frontal (F) scalp and temporal
arallel to the median sagittal line (M), and CP is perpendicular to CF. P
iagram of the puncture point on the body surface. Here, the distance
from the OML to P on the body surface is equal to the height (mm)
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The primary outcome was death at 30 days after onset.
Functional independence was assessed at 1 year using the
Glasgow Outcome Scale [12] (GOS, scores range from 1
to 5, score 1 indicating death, ≥4 indicating functional
independence, with lower scores indicating greater dis-
ability). The follow-up was completed by observer-blind
neurologists via telephone or via an interview with the
patient or their relative.
Statistics
Measurement data were expressed as “x  s” when the
data were distributed normally; otherwise, the data were
expressed as “M (Q1 ~Q3)”. Baseline grouped measure-
ment data that met the normality and homogeneity of
variances criteria were analyzed using Student’s t test;
otherwise, the Wilcoxon rank sum test was used. Chi-Table 1 Clinic baseline characteristics
Characteristics All patients
(n = 198)
Age, mean ± SD (range) 57.1 ± 12.8 (31–95) 59
≦60, n (%) 49.5 ± 6.7, 130 (65.7) 48
> 60, n (%) 71.5 ± 8.3, 68 (34.3) 72
Female/Male, n (%) 54 (27.3)/144 (72.7) 2
Diabetes, No/Yes, n (%) 127 (64.1)/71 (35.9) 6
Time from ictus to operation, h
Median (25%, 75%) 7 (5, 9)
BP (mm Hg), mean ± SD
SBP 188.1 ± 26.4
DBP 103.4 ± 12.1
GCS, mean ± SD 8.1 ± 3.4
15-13, n (%) 30 (15.2)
12-7, n (%) 88 (44.4)
6-3, n (%) 80 (40.4)
NIHSS, mean ± SD 20.8 ± 5.3
<15, n (%) 32 (16.2)
15-20, n (%) 50 (25.3)
>20, n (%) 116 (58.6)
HV, mL (Range) 56.7 ± 23.0 ( 30–144) 53
≦60 mL, n (%) 43.12 ± 8.9, 131 (66.2) 41






P values were calculated using the Chi-square , Student’s t (a) or Wilcoxon rank sum
craniectomy; BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood p
Scale; HV: hematoma volume; IVH: intraventricular hemorrhage.square or rank sum tests were used for categorical data.
Because the outcome variable was ordinal, the Wilcoxon
rank sum test was used to compare the difference between
groups. Prognostic factors were analyzed using binary
logistic regression (forward conditional method). For
patients lost during follow-up, the patients’ last obser-
vation was considered as the final outcome status to be
included in the intention-to-treat analysis. All analyses
were performed with SPSS 18.0. P <0.05 was considered
to be a statistically significant difference.
Results
General result
Baseline data are shown in Table 1 and Figure 2. A total
of 553 consecutive patients with spontaneous ICH in the
basal ganglia were admitted. Of these patients, 355 were
excluded (most for having HV < 30 mL, refusing theGroups P
A (n = 84) B (n = 114)
.4 ± 14.5 (31–95) 55.3 ± 11.1 (36–87) 0.025a
.4 ± 7.2, 45 (53.6) 50.0 ± 6.4, 85 (74.6) 0.209a
.1 ± 9.5, 39 (46.4) 70.9 ± 6.4, 29 (25.4) 0.562a
2 (26.2)/62 (73.8) 32 (28.1)/82 (71.9) 0.769
0 (71.4)/24 (28.6) 67 (58.8)/47 (41.2) 0.066
0.123b
7 (6, 10) 6 (5, 9)
185.9 ± 24.5 189.8 ± 27.7 0.300a
102.1 ± 11.1 104.3 ± 12.7 0.108a
8.6 ± 3.6 7.8 ± 3.2 0.082
17 (20.2) 13 (11.4) 0.111b
37 (44.0) 51 (44.7)
30 (35.7) 50 (43.9)
20.2 ± 5.5 21.2 ± 5.1 0.194
17 (20.2) 15 (13.2) 0.163 b
22 (26.2) 28 (24.6)
45 (53.6) 71 (62.3)
.7 ± 23.4 (30–144) 58.9 ± 22.5 (30–128) 0.119a
.9 ± 8.9, 61 (72.6) 44.2 ± 8.8, 70 (61.4) 0.142a
.0 ± 21.1, 23 (27.4) 82.2 ± 17.3, 44 (38.6) 0.560 a
0.219b
30 (35.7) 34 (29.8)
27 (32.1) 35 (30.7)
15 (17.9) 21 (18.4)
12 (14.3) 24 (21.1)
tests (b). Groups: A, minimal invasive puncture and drainage; B, decompressive
ressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes of Health Stroke
Figure 2 Trial profile. A total of 553 consecutive patients with ICH were admitted. Of these patients, 492 were admitted to the General Hospital
of Beijing Military Region and 61 were admitted to the Xianghe Hospital. Based on the inclusion/exclusion criteria, 355 were excluded, and 198
were available according to the per protocol sample. Of those, 84 received minimally invasive puncture and drainage (group A), and 114 underwent
decompressive craniectomy (group B) hematoma evacuations. Nine were lost during follow up at 30 days (1 and 4) and 1 year (1 and 3 in group A
and group B, respectively). For those patients, their last observed data were used as their final results for intention-to-treat analysis.
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fore, 198 patients were available for this study, including
9 cases that were lost during follow up. There were 84
cases in group A and 114 cases in group B, of which 2
and 7 were lost in each group, respectively, during
follow up. The mean age was 57.1 ± 12.8 years (ranged
31–95), and the age of group A was older than group B
(59.4 ± 14.5 vs. 55.3 ± 11.1 years, P = 0.025). The mean
HV was 56.7 ± 23.0 mL (ranged 10–144 mL). Patients
with IVH accounted for 67.7% of the total patient
population used. Except for age, there were no other
significant differences between the two groups in their
baseline data, including gender, blood pressure, initial
GCS, NIHSS and the time from ictus to operation.
Short-term outcome
Table 2 shows the outcomes at 30 days after ictus. The
cumulative total mortality was 32.3% (64/198), and the
difference between group A (27.4%) and group B (36.0%)
was not statistically significant (OR = 1.490, 95% CI
0.807 ~ 2.751, P = 0.203). Additionally, no significant
difference was observed between the two groups in the
incidence of complications (RB, PI, RF and UGB) and
their corresponding mortality. In addition, the incidenceof secondary intracranial infection (0 and 2 in groups A
and B, respectively) and required reoperation (0 and 2
in groups A and B, respectively) was indistinguishable
between the groups.
Further analysis using stratified variables indicated that
for patients ≦60 years of age, NIHSS <15, or HV≦60 mL,
the mortality of group A was significantly lower than that
of group B. For patients with severe IVH, the mortality of
group B was significantly lower than that of group A.
Univariate analysis showed that for patients with DM,
GCS≦ 6, NIHSS > 20, HV > 60 mL or IVH >4 or with
complications (RB, RF or PI), the risk of mortality at
30 days after ictus was significantly increased.
Logistic regression analysis (Table 3) using the raw
data revealed that after adjusting for age, sex and other
factors, independent predictors of 30-day mortality in-
cluded a lower baseline GCS and the presence of IVH
combined with RB and RF. For a patient with RB or RF,
the risk of death increased to more than 13 or 3 times,
respectively.
The cumulative total favorable outcome (GOS > 3) at
30 days post onset was 10.6% (21/198), i.e., only 21 of
the 134 survivors were functionally independent. There
was no significant difference between group A and
Table 2 Mortality at 30 days
All Patients n (%) Groups














Total 64 (32.3) 134 (67.7) 23 (27.4) 61 (72.6) 84 41 (36.0) 73 (64.0) 114 0.203
Age 0.203
≦60 42 (32.3) 88 (67.7) 0.995 9 (20.0) 36 (80.0) 45 33 (38.8) 52 (61.2) 85 0.030
> 60 22 (32.4) 46 (67.6) 14 (35.9) 25 (64.1) 39 8 (27.6) 21 (72.4) 29 0.472
Gender 0.203
Female 14 (25.9) 40 (74.1) 0.240 4 (18.2) 18 (81.8) 22 10 (31.3) 22 (68.8) 32 0.286
Male 50 (34.7) 94 (65.3) 19 (30.6) 43 (69.4) 62 31 (37.8) 51 (62.2) 82 0.373
Diabetes 0.203
No 34 (26.8) 93 (73.2) 0.026 12 (20.0) 48 (80.0) 60 22 (32.8) 45 (67.2) 67 0.104
Yes 30 (42.3) 41 (57.7) 11 (45.8) 13 (54.2) 24 19 (40.4) 28 (59.6) 47 0.665
GCS <0.001 0221
15-13 grade 1 2 (6.7) 28 (93.3) 0 (0.0) 17 (100.0) 17 2 (15.4) 11 (84.6) 13 0.179
12-7 grade 2 21 (23.9) 67 (76.1) 0.059a 7 (18.9) 30 (81.1) 37 14 (27.5) 37 (72.5) 51 0.357
6-3 grade 3 41 (51.3) 39 (48.8) <0.001b 16 (53.3) 14 (46.7) 30 25 (50.0) 25 (50.0) 50 0.477
NIHSS 0.001 0.221
<15 grade 1 5 (15.6) 27 (84.4) 0 (0.0) 17 (100) 17 5 (33.3) 10 (66.7) 15 0.015
15-20 grade 2 9 (18.0) 41 (82.0) 1.000.a 3 (13.6) 19 (86.4) 22 6 (21.4) 22 (78.6) 28 0.713
>20 grade 3 50 (43.1) 66 (56.9) 0.002b 20 (44.4) 25 (55.6) 45 30 (42.3) 41 (55.7) 71 0.817
HV, mL 0.203
≦60 29 (22.1) 102 (77.9) <0.001 8 (13.1) 53 (86.9) 61 21 (30.0) 49 (70.0) 70 0.021
> 60 35 (52.5) 32 (47.8) 15 (65.2) 8 (34.8) 23 20 (45.5) 24 (54.5) 44 0.127
IVH <0.001 0.221
0 12 (18.8) 52 (81.3) 3 (10.0) 27 (90.0) 30 9 (26.5) 25 (73.5) 34 0.117
1-4 grade 1 10 (16.1) 52 (83.9) 0.816c 3 (11.1) 24 (88.9) 27 7 (20.0) 28 (80.0) 35 0.491
5-8 grade 2 19 (52.8) 17 (47.2) <0.001a 6 (40.0) 9 (60.0) 15 13 (61.9) 8 (38.1) 21 0.201
9-12 grade 3 23 (63.9) 13 (36.1) 0.471b 11 (91.7) 1 (8.3) 12 12 (50.0) 12 (50.0) 24 0.025
Complications, n (%)
RB 0.221
No 57 (30.2) 132 (69.8) 0.006 22 (26.5) 61 (73.5) 83 35 (33.0) 71 (67.0) 106 0.334
Yes 7 (77.8) 2 (22.2) 1 (100) 0 (0.0) 1 6 (75.0) 2 (25.0) 8 1.000
RF 0.221
NO 50 (28.2) 127 (71.8) 0.001 19 (24.1) 60 (75.9) 79 31 (31.6) 67 (68.4) 98 0.267
Yes 14 (66.7) 7 (33.3) 4 (80.0) 1 (20.0) 5 10 (62.5) 6 (37.5) 16 0.624
PI 0.203
No 31 (26.7) 85 (73.3) 0.046 12 (24.0) 38 (76.0) 50 19 (28.8) 47 (71.2) 66 0.566
Yes 33 (40.2) 49 (59.8) 11 (32.4) 23 (67.6) 34 22 (45.8) 26 (54.2) 48 0.223
UGB 0.221
No 56 (30.6) 127 (69.4) 0.087 19 (24.7) 58 (75.3) 77 37 (34.9) 69 (65.1) 106 0.139
Yes 8 (53.3) 7 (46.7) 4 (57.1) 3 (42.9) 7 4 (50.0) 4 (50.0) 8 1.000
P values were calculated using the Wilcoxon or Kruskal-Wallis rank sum tests. Groups: A, minimal invasive puncture and drainage; B, decompressive craniectomy;
GOS: Glasgow Outcome Scale; BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood pressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes
of Health Stroke Scale; HV: hematoma volume; IVH: intraventricular hemorrhage; RB: rebleed; PI: pulmonary infection; RF: renal failure; UGB: upper gastrointestinal
bleeding; agrade 1 vs. grade 2; bgrade 2 vs. grade 3; cIVH 0 vs. IVH grade 1.
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Long-term outcome
Table 4 shows that the cumulative total mortality at
1 year after ictus was 43.4% (86/198) and that the differ-
ence between group A and group B was not significant
(36.1% vs. 48.2%, P = 0.112).
Further analysis using stratified variables showed that
for patients ≦60 years of age, NIHSS <15, HV≦60 mL,
no IVH, or no UGB, the 1-year mortality of group A
was significantly lower than that for group B. For
patients with IVH scores of 9–12, the 1-year mortality of
group B was obviously lower than that of group A. Other
stratified variables showed no significant differences
between groups.
Using univariate analysis, higher mortality was shown
to be closely related with DM (53.5%), initial GCS≦6
(67.5%), NIHSS > 20 (57.8%), HV > 60 mL (67.2%) and
IVH > 4 (75%) and also with any complication, RB
(77.8%), RF (85.7%), PI (58.5%) and UGB (73.3%).
Using multivariate analysis (Table 5) on the raw data
after being adjusted for other factors, age, GCS, HV,
IVH, RB and RF were determined to be independent risk
factors for fatality at 1 year: the higher the initial GCS
score, the lower the risk of death at 1 year after onset. If
a patient had RB or RF complications, the risk of death
at 1 year was increased by 8 or 6 times, respectively.
The 1-year prognosis-based GOS showed favorable
outcomes in 39.3% of the patients in group A and in
17.5% of patients in group B (P = 0.001, Table 6); therefore,
the absolute difference in the favorable outcome between
MIPD and DC was 21.8% (OR = 0.329, 95% CI 0.171 to
0.631, P = 0.001). Logistic regression analysis indicated
that different treatments, age, GCS, HV, IVH and PI were
all significant factors for favorable outcomes at 1 year
(Table 7). Specifically, MIPD treatment, younger age,
higher initial GCS, less HV and the absence of IVH/PI
were associated with more favorable outcomes at 1 year








GCS −0.162 0.065 6.156 1 0.013 0.850 0.748 0.967
IVH 0.194 0.049 15.818 1 0.000 1.214 1.103 1.335
RB 2.574 0.890 8.354 1 0.004 13.113 2.290 75.099
RF 1.227 0.566 4.706 1 0.030 3.410 1.126 10.331
Constant −3.184 0.587 29.451 1 <.001 0.041
Method: Forward conditional; Entry 0.05, Removal: 0.10, Classification cutoff:
0.5. Dependent: outcome at 30-day of ictus: 0 = survival, 1 = dead. IVH:
intraventricular hemorrhage; RB: rebleed, 0 = no, 1 = yes; RF: renal failure,
0 = no, 1 = yes. All covariates used were original data.Discussion
The mass effect of a hematoma can lead to brain damage,
such as intracranial hypertension or a cerebral hernia.
Some evidence suggests that the mass effect caused by HV
(<60 mL) is not the dominant injury mechanism; rather,
excitotoxic substances released from the hematoma, such
as elevated glutamate levels in the perihematomal region,
may have an important impact on secondary cerebral
injury [13]. Therefore, the effective removal of the
hematoma at the acute phase is crucial for the effective
treatment of ICH and would allow for reducing mortality
and improving long-term quality of life.
Surgical removal of the bone flap is a classical technique
for treating ICH; it is characterized by good visibility,
complete removal of the hematoma, easy hemostasia, and
a reduction of resultant pressure. However, there are also
some shortcomings associated with the procedure, such as
general anesthesia, duration of the surgery, possible brain
distortion, possible damage to the brain tissue around
the hematoma by electrocoagulation, rebleeding, and a
potential for a series of pathophysiological changes post
operation (such as disturbance in water and electrolytes)
that can result in the severe impairment of neurological
functions and multiple complications.
Several published randomized trials show that there is
no benefit from conventional surgery compared with
conservative medical treatment; [14,15] for severe cases,
the mortality from DC is as high as 64.7%, and elderly
patients rarely survive [16]. The STICH trial [5] failed to
demonstrate the assumed superiority of operative treatment
over conservative management. The study included 1033
patients (between 19 and 93 years of age; HV between 4
and 210 mL) from 83 participating centers in 27 countries.
There was no significant difference in mortality or favorable
outcomes between the two groups at 6 months post ictus.
Although craniotomy may be helpful in treating patients
with lobar clots within 1 cm of the surface that present
with GCS > 9, patients in the STICH study with a deep
hematoma or with GCS < 8 tended to fare worse with
surgical removal compared with medical management.
The recently completed randomized STICH II trial [6]
included 601 patients from 78 centers in 27 countries with
superficial lobar ICH, a mean age of 65 years, a mean HV
of 37 mL (ranged 10–100 mL), and no IVH. The study
further indicated that early surgery (99% craniotomy and
1% minimally invasive procedures to evacuate the hemato-
mas within 12 h of ictus) had no significant difference in
6-month mortality (18% and 24%) and good outcome rates
(41% and 38%), compared with conservative treatment.
The guidelines for the management of spontaneous ICH
by the American Heart Association/American Stroke
Association in 2010 [17] recommended that for patients
presenting with lobar clots of >30 mL and within 1 cm
of the surface, the evacuation of supratentorial ICH by
Table 4 Morality at 1 year after ICH onset
All patients n (%) Groups
A (n = 84) B (n = 114)
Dead Alive P Dead Alive Total Dead Alive Total P
86 (43.4) 112 (56.6) 31 (36.1) 53 (63.9) 84 55 (48.2) 59 (51.8) 114 0.112
Age 0.112
≦60 50 (38.5) 80 (61.5) 0.052 11 (24.4) 34 (75.6) 45 39 (45.9) 46 (51.4) 85 0.017
> 60 36 (52.9) 32 (47.1) 20 (51.3) 19 (48.7) 39 16 (55.2) 19 (48.7) 39 0.752
Gender 0.112
Female 22 (40.7) 32 (59.3) 0.640 9 (40.9) 13 (59.1) 22 13 (40.6) 19 (59.4) 32 0.983
Male 64 (44.4) 80 (55.6) 22 (35.5) 40 (64.5) 62 42 (51.2) 40 (48.8) 82 0.061
Diabetes 0.112
No 48 (37.8) 79 (62.2) 0.033 18 (30.0) 42 (70.0) 60 30 (44.8) 37 (55.2) 67 0.088
Yes 38 (53.5) 33 (46.5) 13 (54.2) 11 (45.8) 24 25 (53.2) 22 (46.8) 47 0.938
GCS <0.001 0.147
15-13 grade 1 3 (10.0) 27 (90.0) 0 (0.0) 17 (100.0) 17 3 (23.1) 10 (76.9) 13 0.070
12-7 grade 2 29 (33.0) 59 (67.0) 0.017a 8 (21.6) 29 (78.4) 37 21 (41.2) 30 (58.8) 51 0.055
6-3 grade 3 54 (67.5) 26 (32.5) <0.001b 23 (76.7) 7 (23.3) 30 31 (62.0) 19 (38.0) 50 0.178
NIHSS <0.001 0.147
<15 grade 1 5 (15.6) 27 (84.4) 0 (0.0) 17 (100.0) 17 5 (33.3) 10 (66.7) 15 0.015
15-20 grade 2 14 (28.0) 36 (72.0) 0.284a 4 (18.2) 18 (81.8) 22 10 (35.7) 18 (64.3) 28 0.175
>20 grade 3 67 (57.8) 49 (42.2) <0.001b 27 (60.0) 18 (40.0) 45 40 (56.3) 31 (43.7) 71 0.698
HV, mL 0.112
≦60 41 (31.3) 90 (68.7) <0.001 13 (21.3) 48 (78.7) 61 28 (40.0) 42 (60.0) 70 0.022
> 60 45 (67.2) 22 (32.8) 18 (78.3) 5 (21.7) 23 27 (61.4) 17 (38.6) 44 0.165
IVH <0.001 0.147
0 16 (25.0) 48 (75.0) 0.918c 3 (10.0) 27 (90.0) 30 13 (38.2) 21 (61.8) 34 0.010
1-4 16 (25.8) 46 (74.2) 5 (18.5) 22 (81.5) 27 11 (31.4) 24 (68.6) 35 0.253
5-8 27 (75.0) 9 (25.0) <0.001a 11 (73.3) 4 (26.7) 15 16 (76.2) 5 (23.8) 21 1.000
9-12 27 (75.0) 9 (25.0) 1.000b 12 (100.0) 0 (0.0) 12 15 (62.5) 9 (37.5) 24 0.036
Complications, n (%)
RB 0.147
No 79 (41.8) 110 (58.2) 0.042 30 (36.1) 53 (63.9) 83 49 (46.2) 57 (53.8) 106 0.164
Yes 7 (77.8) 2 (22.2) 1 (100.0) 0 1 6 (75.0) 2 (25.0) 8 1.000
RF 0.147
NO 68 (38.4) 109 (61.6) <0.001 26 (32.9) 53 (67.1) 79 42 (42.9) 56 (57.1) 98 0.177
Yes 18 (85.7) 3 (14.3) 5 (100.0) 0 5 13 (81.3) 3 (18.8) 16 0.549
PI 0.147
No 38 (32.8) 78 (67.2) <0.001 13 (26.0) 37 (74.0) 50 25 (37.9) 41 (62.1) 66 0.179
Yes 48 (58.5) 34 (41.5) 18 (52.9) 16 (47.1) 34 30 (62.5) 18 (37.5) 48 0.496
UGB 0.147
No 75 (41.0) 108 (59.0) 0.027 25 (32.5) 52 (67.5) 77 50 (47.2) 56 (52.8) 106 0.046
Yes 11 (73.3) 4 (26.7) 6 (85.7) 1 (14.3) 7 5 (62.5) 3 (37.5) 8 0.569
P values were calculated using the Wilcoxon or Kruskal-Wallis rank sum tests. Groups: A, minimal invasive puncture and drainage; B, decompressive craniectomy;
BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood pressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes of Health Stroke Scale; HV:
hematoma volume; IVH: intraventricular hemorrhage; RB: rebleed; PI: pulmonary infection; RF: renal failure; UGB: upper gastrointestinal bleeding; agrade 1 vs. grade
2; bgrade 2 vs. grade 3; cIVH 0 vs. IVH grade 1.
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B S.E. Wald df Sig. Exp(B) 95% CI
Lower Upper
Age 0.029 0.014 4.185 1 0.041 1.030 1.001 1.059
GCS −0.172 0.066 6.782 1 0.009 0.842 0.739 0.958
HV 0.021 0.010 4.220 1 0.040 1.021 1.001 1.042
IVH 0.182 0.051 12.588 1 0.000 1.200 1.085 1.327
RB 2.170 0.935 5.389 1 0.020 8.758 1.402 54.706
RF 1.881 0.730 6.636 1 0.010 6.561 1.568 27.448
Constant −2.752 1.172 5.512 1 0.019 0.064
Method: Forward conditional; Entry 0.05, Removal: 0.10, Classification cutoff: 0.5.
Dependent: outcome at 1-year of ictus: 0 = survival, 1 = dead. GCS: Glasgow
Coma Scale; HV: hemorrhagic volume; IVH: intraventricular hemorrhage; RB:
rebleed, 0 = no, 1 = yes; RF: renal failure, 0 = no, 1 = yes; All covariates used
were original data.
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http://www.mmrjournal.org/content/1/1/10standard craniotomy may be considered; however, for
most patients with supratentorial deep ICH, the usefulness
of DC is uncertain. An ideal technique for ICH evacuation
would be one that minimizes brain manipulation and
that could also be performed under minimal anesthesia,
preferably at the bedside. The 2007 consensus conference
sponsored by the U.S. National Institutes of Health used
favorable results of a number of studies and case reports
to note that minimally invasive techniques to evacuate
clots appear to be a promising area that warrants further
investigation [18].
MIPD has become more attractive than DC for treating
ICH for the following reasons. First, the YL-1 type punc-
ture needle is designed with a 3.2-mm outer diameter for
minimizing the potential exacerbation of secondary brain
trauma by avoiding the need for a craniectomy and a brain
retraction. Second, the YL-1 type puncture needle has a
built-in aiguille for perforating through the skull and
dura and has an additional washing needle to replace
the aiguille after drilling is complete. For flushing the
hematoma, the washing liquid is pushed by a syringe and
is ejected from the distal end in all directions, helping to
liquefy, dissolve and drain the coagulated clot. Third,
the operation can be accomplished at the bedside under
local anesthesia in approximately half an hour. For
these reasons, it has been widely adopted in China.
However, there are few studies that compare the effi-
cacies of MIPD and DC for deep ICH. The randomized
trial by Zhou et al. [19] showed that compared with DC,
MIPD did not decrease short-term mortality but signifi-
cantly improved long-term outcomes.
In the present study, the 30-day mortality rates of
groups A and B were similar (27.4% vs. 36.0%, P = 0.203);
however, good outcomes at 1 year (39.3% vs.17.5%
P < 0.001) were significantly higher for the MIPD
group. Although our MIPD results were similar to
those in the STICH II study, all of the patients inSTICH II had superficial lobar hemorrhages, absent of
IVH, and more than half were fully conscious, whereas
all of our patients had hemorrhages at supratentorial
deep locations, 67.7% presented with IVH, and 84.8%
had a GCS score≦12. The remarkable difference in the
favorable long-term outcomes between STICH II and
our study suggests that MIPD may be more helpful in
improving the neurologic functional outcome of patients
with ICH.
Logistic regression analysis revealed that the risk factors
for 30-day mortality were GCS, IVH, RB and RF (Table 3).
Different treatments, age, GCS, HV, IVH and PI were
important factors that impacted the favorable outcomes
at 1 year (Table 7).
Age was correlated with ICH prognosis: the older the
patients, the higher their risk of death (Table 5); the
younger, the greater the likelihood of a favorable out-
come (Table 7). For patients ≦60 years of age, both the
30-day and 1-year mortalities of group A were significantly
lower, and the 1-year good outcomes were significantly
higher than those for group B. For patients older than
60 years of age, there was no noticeable difference in
short- or long-term outcomes between the groups. This
result implies that MIPD treatment can improve the treat-
ment prognosis for younger patients with ICH.
GCS is the most common scoring system used to
describe the level of consciousness and the severity of
disability of a patient with brain injury. It correlates
well with outcomes following severe brain injury [20].
Our data showed that the 30-day mortality of patients
with initial GCS scores of 15–13, 12–7 and 6–3, was
6.7%, 23.9% and 51.3%, respectively; the 1-year mortality
was 10.0%, 33.0% and 67.5% and the 1-year favorable out-
come was 53.3%, 37.5% and 5.0%, respectively. The 1-year
good outcome rates for patients with mild to moderate
disturbances of consciousness in group A were more
than twice as high as those in group B (70.6% vs. 30.8%,
P = 0.033; 51.4% vs. 27.5%, P = 0.023). This result indi-
cates that MIPD significantly increased the long-term
good outcome rate for patients with mild to moderately
impaired consciousness.
HV is an important prognosis-associated factor. For
patients with HV > 60 mL, the mortality rates at 30 days
(52.5%) and 1 year (67.2%) post ictus were two times
higher than those with HV < 60 mL (22.1% and 31.3%,
respectively, all P <0.001), and there was no significant
difference between groups A and B. By contrast, for
patients with HV≦60 mL, the mortality in group A at 30
days (13.1%) and 1 year (21.3%) was significantly lower
than those for group B (30.0% and 40.0%, respectively,
all P < 0.05). The favorable outcome rate at 1 year was
significantly higher in group A than that in group B
(52.5% vs. 27.1%, P = 0.003). These results suggest that
patients with HV≦60 mL may benefit from the treatment
Table 6 Comparison of good outcome at 1 year
All Patients n (%) Groups














145 (73.2) 53 (26.8) 51 (60.7) 33 (39.3) 84 94 (82.5) 20 (17.5) 114 0.001
Age 0.001
≦60 85 (65.4) 45 (34.6) 0.001 18 (40.0) 27 (60.0) 45 67 (78.8) 18 (21.2) 85 <0.001
> 60 60 (88.2) 8 (11.8) 33 (84.6) 6 (15.4) 39 27 (93.1) 2 (6.9) 29 0.451
Gender 0.001
Female 40 (74.1) 14 (25.9) 0.870 15 (68.2) 7 (31.8) 22 25 (78.1) 7 (21.9) 32 0.417
Male 105 (72.9) 39 (27.1) 36 (58.1) 26 (41.9) 62 69 (84.1) 13 (15.9) 82 0.001
Diabetes 0.001
No 85 (66.9) 42 (33.1) 0.008 32 (53.3) 28 (46.7) 60 53 (79.1) 14 (20.9) 67 0.002
Yes 60 (84.5) 11 (15.5) 19 (79.2) 5 (20.8) 24 41 (87.2) 6 (12.8) 47 0.490
GCS <0.001 0.004
15-13 (grade 1) 14 (46.7) 17 (53.3) 5 (29.4) 12 (70.6) 17 9 (69.2) 4 (30.8) 13 0.033
12-7 (grade 2) 55 (62.5) 33 (37.5) 0.130a 18 (48.6) 19 (51.4) 37 37 (72.5) 14 (27.5) 51 0.023
6-3 (grade 3) 76 (95.0) 4 (5.0) <0.001b 28 (93.3) 2 (6.7) 30 48 (96.0) 2 (4.0) 50 0.705
NIHSS <0.001 0.001
<15 (grade 1) 15 (46.9) 17 (53.1) 4 (23.5) 13 (76.5) 17 11 (73.3) 4 (26.7) 15 0.006
15-20 (grade 2) 28 (56.0) 22 (44.0) 0.422a 10 (45.5) 12 (54.5) 22 18 (64.3) 10 (35.7) 28 0.187
>20 (grade 3) 102 (87.9) 14 (12.1) <0.001b 37 (82.2) 8 (17.8) 45 65 (91.5) 6 (8.5) 71 0.135
HV , mL 0.001
≦60 80 (61.1) 51 (38.9) <0.001 29 (47.5) 32 (52.5) 61 51 (72.9) 19 (27.1) 70 0.003
> 60 65 (97.0) 2 (3.0) 22 (95.7) 1 (4.3) 23 43 (97.7) 1 (2.3) 44 1.000
IVH <0.001 0.001
0 31 (48.4) 32 (51.6) 10 (33.3) 20 (66.7) 30 21 (61.8) 13 (38.2) 34 0.024
1-4 (grade 1) 43 (69.4) 19 (30.6) 0.018c 14 (51.9) 13 (48.1) 27 29 (82.9) 6(17.1) 35 0.009
5-8 (grade 2) 36 (100.0) 0 <0.001a 15 (100.0) 0 15 21 (100.0) 0 21 1.000
9-12 (grade 3) 35 (97.2) 1 (2.8) 1.000 12 (100.0) 0 12 23 (95.8) 1 (4.2) 24 1.000
Complications, n (%)
RB 0.001
No 136 (72.0) 53 (28.0) 0.116 50 (60.2) 33 (39.8) 83 86 (81.1) 20 (18.9) 106 0.002
Yes 9 (100.0) 0 1 (100.0) 0 1 8 (100) 0 8 1.000
RF 0.001
NO 124 (70.1) 53 (29.9) 0.003 46 (58.2) 33 (41.8) 79 78 (79.6) 20 (20.4) 98 0.002
Yes 21 (100.0) 0 5 (100.0) 0 5 16 (100.0) 0 16 1.000
PI 0.001
No 70 (60.3) 46 (39.7) <0.001 22 (44.0) 28 (56.0) 50 48 (72.7) 18 (27.3) 66 0.002
Yes 75 (91.5) 7 (8.5) 29 (85.3) 5 (14.7) 34 46 (95.8) 2 (4.2) 48 0.120
UGB 0.001
No 131 (71.6) 52 (28.4) 0.075 44 (57.1) 33 (42.9) 77 87 (82.1) 19 (17.9) 106 <0.001
Yes 14 (93.3) 1 (6.7) 7 (100.0) 0 7 7 (87.5) 1 (12.5) 8 1.000
P values were calculated using the Wilcoxon or Kruskal-Wallis rank sum tests. Groups: A, minimal invasive puncture and drainage; B, decompressive craniectomy;
GOS: Glasgow Outcome Scale; BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood pressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes
of Health Stroke Scale; HV: hematoma volume; IVH: intraventricular hemorrhage; RB: rebleed; PI: pulmonary infection; RF: renal failure; UGB: upper gastrointestinal
bleeding; agrade 1 vs. grade 2; bgrade 2 vs. grade 3; cIVH 0 vs. IVH grade 1.
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Table 7 Binary logistic regression analyze of good
outcome factors at 1 year
Variables B S.E. Wald df Sig. Exp(B) 95% CI
Lower Upper
Group −1.274 0.504 6.381 1 0.012 0.280 0.104 0.752
Age −1.538 0.581 7.004 1 0.008 0.215 0.069 0.671
GCS 0.171 0.082 4.352 1 0.037 1.187 1.010 1.395
HV −0.059 0.021 8.065 1 0.005 0.943 0.906 0.982
IVH −0.423 0.132 10.268 1 0.001 0.655 0.506 0.849
PI −1.556 0.554 7.900 1 0.005 0.211 0.071 0.624
Constant 5.503 1.717 10.276 1 0.001 245.452
Method: Forward conditional; Entry 0.05, Removal: 0.10, Classification cutoff:
0.5. Dependent: outcome at 1-year of ictus: 0 = bad, 1 = favorable (Glasgow
Outcome Scale score≧3); Group: 1 = minimal invasive puncture and drainage,
2 = decompressive craniectomy; GCS: Glasgow Coma Scale; HV: hemorrhagic
volume; IVH: intraventricular hemorrhage; PI: pulmonary infection, 0 = no,
1 = yes. All covariates used were original data except for Age (1, ≦60 years;
2, >60 years).
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HV > 60 mL, in terms of decreasing mortality and
increasing neurologic functional independence.
IVH secondary to ICH is a powerful and independent
risk factor for poor prognosis, particularly severe IVH.
The mortality at 30 days can be as high as 91.7% [1].
The high mortality of IVH is related to the volume of
IVH, obstruction of cerebrospinal fluid circulation, [21]
and toxic effects of ventricular blood clots, which could
lead to secondary cerebral vasospasms and acute obstruct-
ive hydrocephalus, especially when the third and fourth
ventricles are involved [22].
In the present study, the incidence of IVH was 67.7%
(134/198). Of those, 36 cases were severe, and the
mortality in group A and group B at 30 days were
91.7% and 50.0% (P = 0.025), respectively, and 100% and
62.5% (P = 0.036), respectively, at 1 year. DC treatment
can be advantageous for reducing mortality in patients
with severe IVH. This benefit can be attributed to the
more thorough evacuation of the hematoma and more
adequate ventricular drainage, which more effectively
reduces the obstruction of the circulation of the cere-
brospinal fluid. However, the favorable outcome in
patients with severe IVH at 1 year was similar between
the two groups.
RB is also an independent risk factor for mortality
(Table 3, Table 5), with an incidence of 4.5% (9/198, 1
case in group A and 8 cases in group B). Among these,
only 2 patients in group B survived at 1-year after ictus
but developed serious disabilities. RF is another poten-
tially fatal complication and had an incidence of 10.6%
(5 cases in group A and 16 cases in group B). All of the
RF cases in group A and 13 of the RF cases in group B
died at 1 year post onset; the remaining 3 cases in group
B survived with dependency. PI and UGB are alsocommon complications of ICH, with incidences of 41.4%
and 7.6%, respectively.
The morbidity rate of the above complications was not
significantly different between the two groups. However,
in patients without these complications, the long-term
good outcome rate was significantly higher in group A
than that in group B (all P <0.01, Table 6). This result
suggests that DC is disadvantageous for neurological
function recovery when performed in patients with these
complications and that the active prevention and treat-
ment of these complications is essential for improving
the prognosis of patients with ICH.
One of the key points of MIPD hematoma evacuation is
to ensure that the coagulated clot is completely liquefied,
as most acute hematomas are solid or semisolid and may
therefore block the drainage system. Thrombolytics have
been used to dissolve coagulated clots to make them more
amenable to be aspirated or drained.
Trials of minimally invasive surgeries in combination
with recombinant tissue plasminogen activator (rtPA)
for ICH evacuation show that rtPA, administered both
intraventricularly and intracerebrally, are safe and effective
for promoting clot dissolution [21,23]. However, due to its
cost, rtPA is not readily available for clot thrombolysis in
ICH patients in China. The patients in group A received
urokinase injections into the hematoma, with only one case
(1.2%) developing RB. Patients in group B did not receive
urokinase injections, and 8 cases (7.0%) developed RB,
implying that RB may not be associated with urokinase.
Conclusion
Our results demonstrate that for patients with hyperten-
sive spontaneous ICH (HV≧30 mL in the basal ganglia),
MIPD may be more effective than DC for achieving a
higher rate of functional independence at 1 year as well
as a lower mortality rate in some patients ≦60 years of
age, with an NIHSS score <15 or HV≦60 mL. For patient
with HV > 60 mL, deep coma or severe IVH, the outcomes
of the two therapies were similar. Further randomized
control trials are needed to assess the benefits of MIPD
for hypertensive spontaneous deep ICH.
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